Tissue-reperfusiuon injury. Atherosclerotic heart disease
Conditions
Interventions
Intervention 1: Erythropoietin (660 U/kg, 5 minutes after the end of cross clamp). Intervention 2: no intervention in control group.
Treatment - Drugs
Erythropoietin (660 U/kg, 5 minutes after the end of cross clamp)
no intervention in control group
Sponsors
Deputy of Research and Technology of Mazandarn University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: sign of angina pectoris need to revascularization after angiography, presence of indication for CABG Exclusion criteria: history of Myocardial Infarction since 3 months prior to the study, EF16 , Cr > 2.5, receiving Erythropoietin since 6 months prior to the study, blood pressure > 150/95, history of Arterial fibrillation blood transfusion since 3 months prior to the study, heavy or cardiac trauma since 3 months prior to the study, polycytemia vera
Exclusion criteria
Exclusion criteria:
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Cardiac marker (CKMB). Timepoint: Before and 10 hours after surgery. Method of measurement: labratory.;Cardiac marker (Troponin I). Timepoint: Before and 10 hours after surgery. Method of measurement: labratory. | — |
Primary
| Measure | Time frame |
|---|---|
| Cardiac function (Wall Motion Score Index). Timepoint: 4 days, 30 days. Method of measurement: echocardiography.;Cardiac function (Ejection Fraction). Timepoint: Before surgery, 4 days and 30 days after surgery. Method of measurement: echocardiography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShervin Ziabakhsh Tabary
Mazandaran University of Medical Sciences
Outcome results
None listed